Cited 36 time in
Truncated and constrained helical analogs of antimicrobial esculentin-2EM
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Thanh Kim Pham | - |
| dc.contributor.author | Kim, Do-Hee | - |
| dc.contributor.author | Lee, Bong-Jin | - |
| dc.contributor.author | Kim, Young-Woo | - |
| dc.date.accessioned | 2024-08-08T05:01:23Z | - |
| dc.date.available | 2024-08-08T05:01:23Z | - |
| dc.date.issued | 2013-12-15 | - |
| dc.identifier.issn | 0960-894X | - |
| dc.identifier.issn | 1464-3405 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/18394 | - |
| dc.description.abstract | Esculentin-2EM is a 37-residue, cationic, amphipathic, alpha-helical antimicrobial peptide isolated from a Korean frog, Glandirama emeljanovi. Many studies revealed that truncation of this peptide results in substantial decreases in its antimicrobial activity. Lee and his colleagues have recently reported that a 23-residue esculentin-2EM analog containing a tryptophanyl substitution at position 16 showed a significant recovery of the antimicrobial activity of the parent peptide. Here we report a new series of 15-residue esculentin-2EM analogs which are constrained into an alpha-helical conformation via an oct-4-enyl cross-link. The resulting 'stapled' derivatives displayed remarkable increases not only in antimicrobial activity but also in helical content and protease resistance compared to Lee's original 23-residue esculentin-2EM analog. The preliminary data obtained in this work strongly supports the potential of our strategy for the development of a new class of peptide antibiotics. (C) 2013 Elsevier Ltd. All rights reserved. | - |
| dc.format.extent | 4 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
| dc.title | Truncated and constrained helical analogs of antimicrobial esculentin-2EM | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1016/j.bmcl.2013.10.031 | - |
| dc.identifier.scopusid | 2-s2.0-84888866276 | - |
| dc.identifier.wosid | 000327787700036 | - |
| dc.identifier.bibliographicCitation | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, v.23, no.24, pp 6717 - 6720 | - |
| dc.citation.title | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
| dc.citation.volume | 23 | - |
| dc.citation.number | 24 | - |
| dc.citation.startPage | 6717 | - |
| dc.citation.endPage | 6720 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalResearchArea | Chemistry | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
| dc.subject.keywordPlus | CLOSING OLEFIN METATHESIS | - |
| dc.subject.keywordPlus | BIOLOGICAL-ACTIVITY | - |
| dc.subject.keywordPlus | STAPLED PEPTIDES | - |
| dc.subject.keywordPlus | GAEGURIN 4 | - |
| dc.subject.keywordPlus | ANTIBIOTICS | - |
| dc.subject.keywordPlus | ACTIVATION | - |
| dc.subject.keywordPlus | MECHANISMS | - |
| dc.subject.keywordPlus | INHIBITOR | - |
| dc.subject.keywordPlus | COMPLEX | - |
| dc.subject.keywordPlus | BINDING | - |
| dc.subject.keywordAuthor | Antimicrobial peptides | - |
| dc.subject.keywordAuthor | alpha-Helix | - |
| dc.subject.keywordAuthor | Stapled peptides | - |
| dc.subject.keywordAuthor | Esculentin-2EM | - |
| dc.subject.keywordAuthor | Proteolytic resistance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
